1177-5491

Biologics Targets and Therapy

Dove Medical Press

View prefix report (10.2147)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 291 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact291 DOIs
2

Deposit reference lists for 111 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Medium impact111 DOIs
3

Attach ORCID iDs across 99 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact99 DOIs

DOIs for this ISSN

Showing the top 5 of 290 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Bezlotoxumab: an emerging monoclonal antibody therapy for pr… (10.2147/btt.s127099)
Abstract References ORCID
120.15 39
2 Botulinum toxin type A products are not interchangeable: a r… (10.2147/btt.s65603)
Abstract References ORCID
119.33 38
3 Efficacy of anti-IL-1 treatment in familial Mediterranean fe… (10.2147/btt.s102954)
Abstract References ORCID
113.89 32
4 Biosimilars and the extrapolation of indications for inflamm… (10.2147/btt.s124476)
Abstract References ORCID
104.85 24
5 Resistant mutations in CML and Ph+ALL – role of po… (10.2147/btt.s50734)
Abstract References ORCID
103.52 23
6 <p>Monoclonal antibody therapy of solid tumors: clinic… (10.2147/btt.s166310)
Abstract References
101.06 104
7 Correlation between HLA haplotypes and the development of an… (10.2147/btt.s145941)
Abstract References ORCID
100.68 21
8 Targeted alpha anticancer therapies: update and future prosp… (10.2147/btt.s29947)
Abstract References ORCID
100.68 21
9 The Current Status of Gene Therapy for the Treatment of Canc… (10.2147/btt.s302095)
Abstract ORCID
97.71 89
10 New frontiers in oncolytic viruses: optimizing and selecting… (10.2147/btt.s140114)
Abstract References ORCID
95.91 18
11 <p>Remicade<sup>®</sup> (infliximab): 20 y… (10.2147/btt.s207246)
Abstract References
95.69 81
12 Cost-effectiveness of routine measuring of serum drug concen… (10.2147/btt.s96982)
Abstract References ORCID
94.15 17
13 Giant-cell tumor of bone: treatment options and role of deno… (10.2147/btt.s57359)
Abstract References ORCID
92.28 16
14 Centrosome – a promising anti-cancer target (10.2147/btt.s87396)
Abstract References ORCID
88.21 14
15 Effects of fucoidan from Fucus vesiculosus in reducing sympt… (10.2147/btt.s95165)
Abstract References ORCID
85.96 13
16 Stem Cell Therapy for Retinal Degeneration: The Evidence to… (10.2147/btt.s290331)
Abstract ORCID
84.06 47
17 Efficacy of ustekinumab against infliximab-induced psoriasis… (10.2147/btt.s169326)
Abstract References ORCID
83.55 12
18 Correlations between immunogenicity, drug levels, and diseas… (10.2147/btt.s97234)
Abstract References ORCID
83.55 12
19 Analytical characterization of recombinant hCG and comparati… (10.2147/btt.s141203)
Abstract References ORCID
78.10 10
20 Biological Therapies for Rheumatoid Arthritis: An Overview f… (10.2147/btt.s252575)
Abstract ORCID
75.93 32
21 Combination of EGFR-TKIs with chemotherapy versus chemothera… (10.2147/btt.s169305)
Abstract References ORCID
75.00 9
22 Advanced basal cell carcinoma, the hedgehog pathway, and tre… (10.2147/btt.s54179)
Abstract References ORCID
75.00 9
23 Patient profiles and clinical utility of mepolizumab in seve… (10.2147/btt.s93954)
Abstract References ORCID
75.00 9
24 Stem Cell Therapy for Burns: Story so Far (10.2147/btt.s259124)
Abstract ORCID
74.57 30
25 Advances with Platelet-Rich Plasma for Bone Healing (10.2147/btt.s290341)
Abstract ORCID
74.57 30
26 Spotlight on dinutuximab in the treatment of high-risk neuro… (10.2147/btt.s114530)
Abstract References
73.12 28
27 Anticholinesterase constituents from the leaves of <em&gt… (10.2147/btt.s136011)
Abstract References
72.36 27
28 New targeted treatments for non-small-cell lung cancer &… (10.2147/btt.s87878)
Abstract References ORCID
71.57 8
29 <p>Systematic review of immunomodulatory therapies for… (10.2147/btt.s199862)
Abstract References
69.90 24
30 <em>CUL4A</em> promotes cell invasion in gastric… (10.2147/btt.s127650)
Abstract References ORCID
67.73 7
31 <p>TRIP6 functions as a potential oncogene and facilit… (10.2147/btt.s191863)
Abstract References ORCID
67.73 7
32 Multikinase inhibitors use in differentiated thyroid carcino… (10.2147/btt.s57619)
Abstract References ORCID
67.73 7
33 Localization and upregulation of survivin in cancer health d… (10.2147/btt.s83864)
Abstract References ORCID
67.73 7
34 <p>Dupilumab side effect in a patient with atopic derm… (10.2147/btt.s195512)
Abstract References
66.11 20
35 Structural and functional comparability study of anti-CD20 m… (10.2147/btt.s187744)
Abstract References ORCID
63.38 6
36 Lipegfilgrastim in the management of chemotherapy-induced ne… (10.2147/btt.s58597)
Abstract References ORCID
63.38 6
37 Safety of biologics in rheumatoid arthritis: data from rando… (10.2147/btt.s68949)
Abstract References ORCID
63.38 6
38 Antidrug antibodies against TNF-blocking agents: correlation… (10.2147/btt.s69606)
Abstract References ORCID
63.38 6
39 Update on sepsis-associated acute kidney injury: emerging ta… (10.2147/btt.s87385)
Abstract References ORCID
63.38 6
40 Eag1 channels as potential early-stage biomarkers of hepatoc… (10.2147/btt.s87402)
Abstract References ORCID
63.38 6
41 Two decades with omalizumab: what we still have to learn (10.2147/btt.s180846)
Abstract References
62.76 17
42 <p>Therapeutic drug monitoring of biologics in psorias… (10.2147/btt.s188286)
Abstract References
61.52 16
43 Mechanism and Applications of CRISPR/Cas-9-Mediated Genome E… (10.2147/btt.s326422)
Abstract
60.46 261
44 Combined treatment with metformin and gefitinib overcomes pr… (10.2147/btt.s166867)
Abstract References
60.21 15
45 The Impact of NK Cell-Based Therapeutics for the Treatment o… (10.2147/btt.s290305)
Abstract ORCID
60.21 15
46 Tocilizumab in refractory rheumatoid arthritis: long-term ef… (10.2147/btt.s101289)
Abstract References ORCID
58.36 5
47 Neutralizing activities against seasonal influenza viruses i… (10.2147/btt.s123831)
Abstract References ORCID
58.36 5
48 Autophagy regulates the stemness of cervical cancer stem cel… (10.2147/btt.s134920)
Abstract References ORCID
58.36 5
49 Efficacy of adalimumab as second-line therapy in a pediatric… (10.2147/btt.s183088)
Abstract References ORCID
58.36 5
50 Apoptosis and the FLIP and NF-kappa B proteins as pharmacody… (10.2147/btt.s57253)
Abstract References ORCID
58.36 5